Pexelizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pexelizumab ?
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized (from mouse)
Target Complement component 5
Clinical data
Legal status
  • investigational
Identifiers
CAS number  YesY
ATC code None
UNII CHZ6OLQ3UU YesY
Chemical data
Formula ?
 YesY (what is this?)  (verify)

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]

Current Status[edit]

Alexion, the developer of pexelizumab stopped development due to disappointing phase 3 results indicating the heart-attack drug is no better than placebo.[5]

References[edit]

  1. ^ ClinicalTrials.gov: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass
  2. ^ ClinicalTrials.gov: Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction
  3. ^ Testa, L; Van Gaal, WJ; Bhindi, R; Biondi-Zoccai, GG; Abbate, A; Agostoni, P; Porto, I; Andreotti, F et al. (2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of thoracic and cardiovascular surgery 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626. 
  4. ^ Mathew, JP; Shernan, SK; White, WD; Fitch, JC; Chen, JC; Bell, L; Newman, MF (2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.". Stroke; a journal of cerebral circulation 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798. 
  5. ^ [1] Analysis: Alexion's pexelizumab fails